

Literatura ACTA MEDICINAE 4/2018 Kazuistiky v onkologii a hematoonkologii

- 2 **Pacientka s karcinomem prsu a Darierovou nemocí, léčená adjuvantní radioterapií**
doc. MUDr. Josef Dvořák, Ph.D. | MUDr. Aneta Rozsypalová Onkologická klinika 1. LF UK a Thomayerova nemocnice, Praha
MUDr. Igor Richter, Ph.D. Oddělení klinické onkologie, Krajská nemocnice Liberec, a. s.
MUDr. Radek Zapletal Onkologická klinika 1. LF UK a Thomayerova nemocnice, Praha
- 2 **Léčba metastatického HER2 pozitivního karcinomu prsu**
MUDr. Lucie Reifová Ústav radiační onkologie, Nemocnice Na Bulovce, Praha
- 2 **Léčba PARP inhibitory**
MUDr. Mária Zvaríková Klinika komplexní onkologické péče, MOÚ, Brno
- 2 **Využití bevacizumabu v léčbě metastatického karcinomu děložního hrdla**
MUDr. Anna Germanová, Ph.D. Gynekologicko-porodnická klinika 1. LF UK a VFN, Praha
- 2 **Karcinom pankreatu**
MUDr. Lenka Ostřížková Interní, hematologická a onkologická klinika LF MU a FN Brno
- 3 **Účinnost sunitinibu v režimu dávkování 2 + 1 v první linii léčby metastatického karcinomu ledviny**
MUDr. Jana Katolická, Ph.D. Onkologicko-chirurgické oddělení, FN u svaté Anny v Brně
MUDr. Petr Filipenský Urologické oddělení, FN u svaté Anny v Brně
MUDr. Jiří Vaníček, Ph.D. Klinika zobrazovacích metod, FN u svaté Anny v Brně
- 3 **Účinnost axitinibu u nemocného v léčbě druhé linie metastazujícího karcinomu ledviny**
doc. MUDr. Milada Zemanová, Ph.D. Onkologická klinika 1. LF UK a VFN, Praha
- 3 **Dobrý efekt bevacizumabu v léčbě u pacientů s NSCLC**
MUDr. Michaela Pařezová Klinika nemocí plicních a TBC, FN Brno
MUDr. Lenka Jakubíková, Ph.D. | prof. MUDr. Jana Skříčková, CSc. Klinika nemocí plicních a TBC FN a LF MU, Brno
- 3 **Mohou tyrosinkinázové inhibitory ovlivnit mozkové metastázy?**
MUDr. Libor Havel Pneumologická klinika 1. LF UK Praha, Thomayerova nemocnice Praha
- 4 **Kompletní odpověď primárního tumoru a regionální lymfadenopatie po léčbě panitumumabem pacientky s generalizovaným adenokarcinomem rekta**
doc. MUDr. Josef Dvořák, Ph.D. | MUDr. Aneta Rozsypalová Onkologická klinika 1. LF UK a Thomayerova Nemocnice, Praha
MUDr. Igor Richter, Ph.D. Oddělení klinické onkologie, Krajská nemocnice Liberec, a. s.
MUDr. Radek Zapletal Onkologická klinika 1. LF UK a Thomayerova Nemocnice, Praha
- 4 **Léčba idelalisibem jako „bridge therapy“ k alogenní transplantaci krvetvorných buněk u nemocného s vysoce rizikovou chronickou lymfocytární leukémií**
MUDr. Martin Šimkovič, Ph.D. IV. interní hematologická klinika, FN Hradec Králové
- 4 **Nivolumab a brentuximab vedotin jako efektivní terapie pacienta s relabujícím/refrakterním Hodgkinovým lymfomem před alogenní transplantací hemopoetických kmenových buněk**
MUDr. Jozef Michalka Interní hematologická a onkologická klinika FN Brno a LF MU, Brno
- 4 **Dasatinib v léčbě chronické myeloidní leukemie s těžkou jaterní toxicitou předchází léčby imatinibem**
MUDr. Daniela Žáčková, Ph.D. Interní, hematologická a onkologická klinika LF MU a FN Brno
- 5 **Obinutuzumab a bendamustin – léčba relabujícího folikulárního lymfomu**
MUDr. Heidi Móciková, Ph.D. Interní hematologická klinika FNKV a 3. LF UK Praha
- 5 **Léčba staršího pacienta s B-CLL kombinací obinutuzumabu s chlorambucilem**
MUDr. Petr Kessler Oddělení hematologie a transfuziologie, Nemocnice Pelhřimov
- 5 **Recidivující respirační infekce u pacienta s refrakternou chronickou lymfocytovou leukémiou liečeného ibrutinibom**
MUDr. Ľudmila Demitrovičová, Ph.D. Oddelenie onkohematológie II., Národný onkologický ústav, Bratislava

Pacientka s karcinomem prsu a Darierovou nemocí, léčená adjuvantní radioterapií

doc. MUDr. Josef Dvořák, Ph.D. | MUDr. Aneta Rozsypalová Onkologická klinika 1. LF UK a Thomayerova nemocnice, Praha

MUDr. Igor Richter, Ph.D. Oddělení klinické onkologie, Krajská nemocnice Liberec, a. s.

MUDr. Radek Zapletal Onkologická klinika 1. LF UK a Thomayerova nemocnice, Praha

- 1 Burkoň, P. – Čoupek, P. – Princ, D., et al.: Zhoubné nádory prsu. In: Šlampa, P., et al.: *Radiační onkologie v praxi*, 2014, 4, s. 333. Masarykův onkologický ústav, Brno.
- 2 Takagi, A. – Kamijo, M. – Ikeda, S.: Darier disease. *J Dermatol*, 2016, 43, s. 275–259.
- 3 Suryawanshi, H. – Dholey, A. – Sharma, A., et al.: Darier disease: A rare genodermatosis. *J Oral Maxillofac Pathol*, 2017, 21, s. 321, doi: 10.4103/jomfp.JOMFP_170_16.
- 4 Podgornii, A. – Ciammella, P. – Ramundo, D. – Iotti, C.: Efficacy of the radiotherapy on Darier's disease: an indirect evidence. *Case Rep Dermatol Med*, 2013, 2013, s. 907802.
- 5 Mac Manus, M. P. – Cavalleri, G. – Ball, D. L., et al.: Exacerbation, then clearance, of mutation-proven Darier's disease of the skin after radiotherapy for bronchial carcinoma: a case of radiation-induced epidermal differentiation? *Radiat Res*, 2001, 156, s. 724–730.

Léčba metastatického HER2 pozitivního karcinomu prsu

MUDr. Lucie Reifová Ústav radiační onkologie, Nemocnice Na Bulovce, Praha

- 1 Slamon, D. J. – Leyland-Jones, B. – Shak, S., et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. *N Engl J Med*, 2001, 344, s. 783–792.
- 2 Baselga, J. – Cortés, J. – Kim, S.-B., et al.: CLEOPATRA Study Group: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. *N Engl J Med*, 2012, 366, s. 109–119.
- 3 Adams, C. W. – Allison, D. E. – Flagella, K., et al.: Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. *Cancer Immunol Immunother*, 2006, 55, s. 717–727.
- 4 Barok, M. – Joensuu, H. – Isola, J.: Trastuzumab emtansine: mechanisms of action and drug resistance. *Breast Cancer Research*, 2014, 16, s. 209, dostupné z: <https://doi.org/10.1186/bcr3621>, vyhledáno 20. 4. 2018.
- 5 Cardoso, F. – Harbeck, N. – Fallowfield, L., et al.: Locally recurrent or metastatic breast cancer: ESMO Practice Guidelines for diagnosis, treatment and follow up. *Ann Oncol*, 2012, 23, suppl. 7, s. viii11–9.
- 6 Vyzula, R., et al.: *Modrá kniha ČOS*. Brno, 22. aktualizace, platnost od 1. 3. 2016; Zhoubný novotvar prsu, kapitola 12.2.2.3 Biologická léčba, pertuzumab indikace.
- 7 Swain, S. M. – Kim, S. B. – Cortés, J., et al.: Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. *Lancet Oncol*, 2013, 14, s. 461–471.
- 8 Balduzzi, S. – Mantarro, S. – Guarneri, V., et al.: Trastuzumab containing regimens for metastatic breast cancer. *Cochrane Database Syst Rev*, 2014, 6, CD006242, doi: 10.1002/14651858.CD006242.pub2.
- 9 Cortés, J. – Baselga, J. – Im, Y. H., et al.: Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer. *Ann Oncol*, 2013, 24, s. 2630–2635.

Léčba PARP inhibitory

MUDr. Mária Zvaríková Klinika komplexní onkologické péče, MOÚ, Brno

- 1 Valerie, K. – Povirk, L. F.: Regulation and mechanisms of mammalian double-strand break repair. *Oncogene*, 2003, 22, s. 5792–5812.
- 2 Sung, P. – Klein, H.: Mechanism of homolog recombination: mediators and helicases take on regulatory functions. *Nat Rev Mol Cell Biol*, 2006, 7, s. 739–750.
- 3 Krejci, L. – Altmannova, V. – Spirek, M. – Zhao, X.: Homologous recombination and its regulation. *Nucleic Acids Res*, 2012, 40, s. 5795–5818.
- 4 d'Adda di Fagagna, F. – Hande, M. P. – Tong, W. M., et al.: Functions of poly(ADP-ribose) polymerase in controlling telomere length and chromosomal stability. *Nat Genet*, 1999, 23, s. 76–80.
- 5 Tong, W. M. – Cortes, U. – Wang, Z. Q.: Poly (ADP-ribose) polymerase: a guardian gel protecting the genome and suppressing tumorigenesis. *Biochim Biophys Acta*, 2001, 1552, s. 27–37.
- 6 Helleday, T. – Petermann, E. – Lundin, C., et al.: DNA repair pathways as targets for cancer therapy. *Nat Rev Cancer*, 2008, 8, s. 193–204.
- 7 Weil, M. K. – Chen, A. P.: PARP inhibitor treatment in ovarian and breast cancer. *Curr Probl Cancer*, 2011, 35, s. 7–50.
- 8 Ledermann, J. – Harter, P. – Gourley, C., et al.: Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving Olaparib maintenance monotherapy: an updated analysis from a randomized, placebo-controlled double-blind, phase 2 trial. *Lancet Oncol*, 2016, 17, s. 1579–1589.
- 9 Matulonis, U. – Harter, P. – Gourley, C., et al.: Olaparib maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and BRCA mutation: overall survival adjusted for postprogression poly (adenosinediphosphate ribose) polymerase inhibitor therapy. *Cancer*, 2016, 122, s. 1844–1852.
- 10 Moore, K. – DiSilvestro, P. – Lowe, E., et al.: SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1/2 mutation (BRCAm). *J Clin Oncol*, 2014, 32, abstrakt TP55616.

Využití bevacizumabu v léčbě metastatického karcinomu děložního hrdla

MUDr. Anna Germanová, Ph.D. Gynekologicko-porodnická klinika 1. LF UK a VFN, Praha

- 1 Ngo, O. – Májek, O. – Krejčí, D. – Mužik, J., et al.: Epidemiologie zhoubných nádorů děložního hrdla v České republice. *Gynekologie a porodnictví*, 2017, 5, s. 270–277.
- 2 Penson, R. T. – Huang, H. Q. – Wenzel, L. B., et al.: Patient reported outcomes in practise changing randomized trial of bevacizumab in the treatment of advanced cervical cancer: An NRG Oncology/Gynecologic Oncology Group study. *Lancet Oncol*, 2015, 16, s. 301–311.
- 3 Poolkerd, S. – Leelakahorn, S. – Manusirivithaya, S., et al.: Survival rate of recurrent cervical cancer patients. *J Med Assoc Thai*, 2006, 89, s. 275–282.
- 4 Gaducci, A. – Tana, R. – Coscio, S., et al.: Treatment options in recurrent cervical cancer (Review). *Oncol Lett*, 2010, 1, s. 3–11.
- 5 Minion, L. E. – Tewari, K. S.: Cervical cancer – state of the science: From angiogenesis blockade to checkpoint inhibition. *Gynecol Oncol*, 2018, 148, s. 609–621.

Karcinom pankreatu

MUDr. Lenka Ostřížková Interní, hematologická a onkologická klinika LF MU a FN Brno

- 1 Buchs, N. C. – Chilcott, M. – Poletti, P. A., et al.: Vascular invasion in pancreatic cancer: Imaging modalities, preoperative diagnosis and surgical management. *World J Gastroenterol*, 2010, 16, s. 818–831.
- 2 Oettle, H. – Post, S. – Neuhaus, P., et al.: Adjuvant chemotherapy with gemcitabine vs. observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. *JAMA*, 2007, 297, s. 267–277.
- 3 Von Hoff, D. D. – Ramanathan, R. K. – Borad, M. J., et al.: Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase III trial. *J Clin Oncol*, 2011, 29, s. 4548–4554. doi: 10.1200/JCO.2011.36.5742, Epub 3. 10. 2011.

Účinnost sunitinibu v režimu dávkování 2 + 1 v první linii léčby metastatického karcinomu ledviny

MUDr. Jana Katolická, Ph.D. Onkologicko-chirurgické oddělení, FN u svaté Anny v Brně

MUDr. Petr Filipenský Urologické oddělení, FN u svaté Anny v Brně

MUDr. Jiří Vaniček, Ph.D. Klinika zobrazovacích metod, FN u svaté Anny v Brně

- 1 Motzer, R. – Hutson, T. – Tomczak, P., et al.: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. *N Engl J Med*, 2007, 356, s. 115–124.
- 2 Rini, B. I. – Cohen, D. P. – Lu, D. R., et al.: Hypertension (HTN) as a biomarker of efficacy in patients (pts) with metastatic renal carcinoma (mRCC) treated with sunitinib. 2010 ASCO Genitourinary Cancers Symposium, abstrakt 312.
- 3 Michaelson, M. D. – Cohen, D. P. – Li, S., et al.: Hand-foot syndrome (HFS) as a potential biomarker of efficacy in patients (pts) with metastatic renal carcinoma (mRCC) treated with sunitinib (SU). 2011 ASCO Genitourinary Cancer Symposium, abstrakt 1320.
- 4 Schmid, T. A. – Gore, M. E.: Sunitinib in the treatment of metastatic renal cell carcinoma. *Ther Adv Urol*, 2016, 8, s. 348–371.
- 5 Lee, J. – Kim, M. – Park, I. – Ahn, J., et al.: Randomized phase II trial of sunitinib four weeks on and two weeks off versus two weeks on and one week off in metastatic clear-cell type renal cell carcinoma: RESTORE trial. *Ann Oncol*, 2015, 26, s. 2300–2305.

Účinnost axitinibu u nemocného v léčbě druhé linie metastazujícího karcinomu ledviny

doc. MUDr. Milada Zemanová, Ph.D. Onkologická klinika 1. LF UK a VFN, Praha

- 1 Lakomy, R. – Poprach, A. – Bortlíček, Z., et al.: Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry. *BMC Cancer*, 2017, 17, s. 880, doi: 10.1186/s12885-017-3901-5.
- 2 Wells, J. C. – Stukalin, I. – Norton, C., et al.: Third-line targeted therapy in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. *Eur Urol*, 2017, 71, s. 204–209.
- 3 Motzer, R. J. – Escudier, B. – Oudard, S., et al.: Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. *Cancer*, 2010, 116, s. 4256–4265.
- 4 Rini, B. I. – Escudier, B. – Tomczak, P., et al.: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. *Lancet*, 2011, 378, s. 1931–1939.
- 5 Motzer, R. J. – Escudier, B. – McDermott, D. F., et al.: Nivolumab versus everolimus in advanced renal-cell carcinoma. *N Engl J Med*, 2015, 373, s. 1803–1813.
- 6 Choueiri, T. K. – Escudier, B. – Powles, T., et al.: METEOR investigators: Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. *Lancet Oncol*, 2016, 17, s. 917–927.
- 7 Motzer, R. J. – Hutson, T. E. – Glen, H., et al.: Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. *Lancet Oncol*, 2015, 16, s. 1473–1482.
- 8 Melichar, B. – Poprach, A. – Kubáčková, K., et al.: Efficacy and tolerability of axitinib in metastatic renal cell carcinoma (mRCC): Comparison of Czech clinical registry and AXIS trial data. European Cancer Congress 2015, abstrakt 2615.

Dobrý efekt bevacizumabu v léčbě u pacientů s NSCLC

MUDr. Michaela Pařezová Klinika nemocí plicních a TBC, FN Brno

MUDr. Lenka Jakubíková, Ph.D. | prof. MUDr. Jana Skříčková, CSc. Klinika nemocí plicních a TBC FN a LF MU, Brno

- 1 Sandler, A. – Gray, R. – Perry, M. C., et al.: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. *M.D. N Engl J Med*, 2006, 355, s. 2542–2550.
- 2 Reck, M. – von Pawel, J. – Zatloukal, P., et al.: Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for non-small-cell lung cancer: AVAIL. *J Clin Oncol*, 2009, 27, s. 1227–1234.
- 3 Adam, Z. – Vorlíček, J., et al.: *Speciální onkologie*. Brno, Masarykova univerzita, 2002.
- 4 Dušek, L. – Májek, O. – Krejčí, D., et al.: Epidemiologie zhoubných nádorů plic, průdušnice a průdušek v ČR. In: Skříčková, J. – Koleč, V., et al.: *Základy moderní pneumoonkologie*. 2017, Maxdorf, Praha, s. 25–27.
- 5 SPC přípravku Avastin.
- 6 Dostupné z: <http://www.uzis.cz/registry-nzls/nor>, vyhledáno 26. 4. 2018.

Mohou tyrosinkinázové inhibitory ovlivnit mozkové metastázy?

MUDr. Libor Havel Pneumologická klinika 1. LF UK Praha, Thomayerova nemocnice Praha

- 1 Jemal, A. – Bray, F. – Center, M. M., et al.: Global cancer statistics. *CA Cancer J Clin*, 2011, 61, s. 69–90. doi:10.3232/caac.20107.
- 2 Schuette, W.: Treatment of brain metastases from lung cancer: chemotherapy. *Lung Cancer*, 2004, 45, suppl. 2, s. 253–710.1016/j.lungcan.2004.
- 3 Langer, C. J. – Mehta, M. P.: Current management of brain metastases, with a focus on systemic options. *J Clin Oncol*, 2005, 23, s. 6207–1910.1200/jco.2005.03.145.
- 4 Lagerwaard, F. J. – Levendag, P. C. – Nowak, P. J., et al.: Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. *Int J Radiat Oncol Biol Phys*, 1999, 43, s. 795–803.10.1016/S0360-3016(98)00442-8.
- 5 Han, G., et al.: A retrospective analysis in patients with EGFR-mutant lung adenocarcinoma: is EGFR mutation associated with a higher incidence of brain metastasis? *Oncotarget*, 2016, 7, s. 56998–57010.
- 6 Stanić, K., et al.: Brain metastases in lung adenocarcinoma: impact of EGFR mutation status on incidence and survival. *Radiol Oncol*, 2014, 48, s. 173–183.
- 7 Rangachari, D., et al.: Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. *Lung Cancer*, 2015, 88, s. 108–111.
- 8 Luo, D. – Ye, X. – Hu, Z., et al.: EGFR mutation status and its impact on survival of Chinese non-small cell lung cancer patients with brain metastases. *Tumour Biol*, 2014, 35, s. 2437–4410.1007/s13277-013-1323-9.
- 9 Jackman, D. M.: A phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer. *Oncotarget*, 2015, 6, s. 4527–4536.
- 10 Katayama, T.: Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma whose how edinitinal good response to gefitinib. *J Thorac Oncol*, 2009, 4, s. 1415–1419.
- 11 Clarke, J. L.: High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. *J Neurooncol*, 2010, 99, s. 283–286.
- 12 Grommes, C.: "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. *Neuro Oncol*, 2011, 13, s. 1364–1369.
- 13 The ASCO Post: Afatinib Shows Clinical Benefit for Non-Small Cell Lung Cancer Patients With Brain Metastases. Posted: 2/1/2016.
- 14 Ballard, P. – Yates, J. W. – Yang, Z., et al.: Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. *Clin Cancer Res*, 2016, 22, s. 5130–5140.
- 15 Goss, G. – Tsai, C. M. – Shepherd, F. A., et al.: CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two Phase II trials. Prezentováno na World Congress on Lung Cancer, Vídeň, Rakousko, 4.–7. 12. 2016. *J Thorac Oncol*, 2017, 12, s. S226, MA15.11.
- 16 Mok, T. S., et al.: CNS response to osimertinib in patients (pts) with T790M-positive advanced NSCLC: Data from a randomized phase III trial (AURA3). *J Clin Oncol*, 2017, 35, suppl., s. 9005–9005.
- 17 Soria, J. C., et al.: Osimertinib in untreated EGFR-mutated advanced non-small cell lung cancer. *N Engl J Med*, 2018, 378, s. 113–125.
- 18 Mok, T., et al.: Prezentováno na ASCO Annual Meeting 2.–6. 6. 2017, Chicago, USA. *J Clin Oncol*, 2017, 36, suppl., abstrakt 9005.
- 19 Vansteenkiste, J., et al.: CNS response to osimertinib vs. standard-of-care EGFR-TKI as first-line treatment in patients with EGFRm advanced NSCLC: FLAURA. Prezentováno na European Society of Medical Oncology (ESMO) Asia 2017 Congress, 17.–19. 11. 2017, Singapur.
- 20 Mok, T. S., et al.: Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. *N Engl J Med*, 2017, 376, s. 629–640.

Kompletní odpověď primárního tumoru a regionální lymfadenopatie po léčbě panitumumabem pacientky s generalizovaným adenokarcinomem rekta

doc. MUDr. Josef Dvořák, Ph.D. | MUDr. Aneta Rozsypalová Onkologická klinika 1. LF UK a Thomayerova Nemocnice, Praha

MUDr. Igor Richter, Ph.D. Oddělení klinické onkologie, Krajská nemocnice Liberec, a. s.

MUDr. Radek Zapletal Onkologická klinika 1. LF UK a Thomayerova Nemocnice, Praha

- 1 Dušek, L. – Pavlík, T. – Májek, O., et al.: Odhady incidence, prevalence a počtu onkologických pacientů léčených protinádorovou terapií v letech 2015 a 2020 – analýza Národního onkologického registru ČR. *Klinická onkologie*, 2015, 28, s. 30–43.
- 2 Douillard, J. Y. – Siena, S. – Cassidy, J., et al.: Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. *J Clin Oncol*, 2010, 28, s. 4697–4705.
- 3 Schwartzberg, L. S. – Rivera, F. – Karthaus, M., et al.: PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. *J Clin Oncol*, 2014, 32, s. 2240–2247.
- 4 Tomásek, J. – Mokrá, L. – Bortlíček, Z.: Panitumumab v 1. linii léčby metastatického kolorektálního karcinomu – výsledky v běžné praxi lepší než v registrační studii. *Farmakoterapie*, 2016, 12, s. 201–204.
- 5 Richter, I. – Dvořák, J. – Bartoš, J., et al.: Aktuální možnosti chemoterapie lokálně pokročilého karcinomu rekta. *Onkologie*, 2015, 9, s. 282–286.

Léčba idelalisibem jako „bridge therapy“ k alogenní transplantaci krvetvorných buněk u nemocného s vysoce rizikovou chronickou lymfocytární leukemií

MUDr. Martin Šimkovič, Ph.D. IV. interní hematologická klinika, FN Hradec Králové

- 1 Dreger, P. – Corradini, P. – Kimby, E., et al.: Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. *Leukemia*, 2007, 21, s. 12–17.
- 2 Dreger, P. – Dohner, H. – Ritgen, M., et al.: Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. *Blood*, 2010, 116, s. 2438–2447.
- 3 Khouri, I. F. – Bassett, R. – Poindexter, N., et al.: Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome. *Cancer*, 2011, 117, s. 4679–4688.
- 4 Furman, R. R. – Sharman, J. P. – Coutre, S. E., et al.: Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. *New Eng J Med*, 2014, 370, s. 997–1007.
- 5 Dreger, P. – Schetelig, J. – Andersen, N., et al.: Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents? *Blood*, 2014, 124, s. 3841–3849.
- 6 Hallek, M. – Cheson, B. D. – Catovsky, D., et al.: Guidelines for diagnosis, indications for treatment, response assessment and supportive management of chronic lymphocytic leukemia. *Blood*, 2018, publikováno online před tiskem.

Nivolumab a brentuximab vedotin jako efektivní terapie pacienta s relabujícím/refrakterním Hodgkinovým lymfomem před alogenní transplantací hemopoetických kmenových buněk

MUDr. Jozef Michalka Interní hematologická a onkologická klinika FN Brno a LF MU, Brno

- 1 Swerdlow, S. H. – Campo, E. – Harris, N. L., et al.: *WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues*. Lyon, France, IARC Press, 2008.
- 2 Küppers, R. – Rajewsky, K.: The origin of Hodgkin and Reed/Sternberg cells in Hodgkin's disease. *Annu Rev Immunol*, 1998, 16, s. 471–493.
- 3 Roemer, M. G. – Advani, R. H. – Ligon, A. H., et al.: PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. *J Clin Oncol*, 2016, 34, s. 2690–2697.
- 4 Freeman, G. J. – Long, A. J. – Iwai, Y., et al.: Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. *J Exp Med*, 2000, 192, s. 1027–1034.
- 5 Yamamoto, R. – Nishikori, M. – Kitawaki, T., et al.: PD-1–PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. *Blood*, 2008, 111, s. 3220–3224.
- 6 Schmitz, N. – Pfister, B. – Sextro, M., et al.: Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. *Lancet*, 2002, 359, s. 2065–2071.
- 7 Moskowitz, C. H. – Nademanee, A. – Masszi, T., et al.: Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet* (London, England), 2015, 385, s. 1853–1862.
- 8 Arai, S. – Fanale, M. – DeVos, S., et al.: Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. *Leuk Lymphoma*, 2013, 54, s. 2531–2533.
- 9 Younes, A. – Gopal, A. K. – Smith, S. E., et al.: Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. *J Clin Oncol*, 2012, 30, s. 2183–2189.
- 10 Chen, R. – Gopal, A. K. – Smith, S. E., et al.: Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Publikováno 18. 7. 2016, doi:10.1182/blood-2016-02-699850.
- 11 Armand, P.: Immune checkpoint blockade in hematologic malignancies. *Blood*, 2015, 125, s. 3393–3400.
- 12 Ansell, S. M. – Lesokhin, A. M. – Borrello, I., et al.: PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. *N Engl J Med*, 2015, 372, s. 311–319.
- 13 Younes, A. – Santoro, A. – Shipp, M.: Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. *Lancet Oncol*, 2016, 17, s. 1283–1294.
- 14 Timmerman, J. M. – Engert, A. – Younes, A., et al.: Checkmate 205 Update with Minimum 12-Month Follow-up: A Phase 2 Study of Nivolumab in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma. *Blood*, 2016, 128, s. 1110.
- 15 Cheson, B. D. – Ansell, S. – Schwartz, L., et al.: Refinement of the Lugano classification lymphoma response criteria in the era of immunomodulatory therapy. *Blood*, 2016, 128, s. 2489–2496.
- 16 Chen, R. – Palmer, J. M. – Popplewell, L., et al.: Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma. *Ann Hematol*, 2011, 90, s. 803–808.
- 17 Sureddi, A. – Robinson, S. – Canals, C., et al.: Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. *J Clin Oncol*, 2008, 26, s. 455–462.
- 18 Perales, M. A. – Ceberio, I. – Armand, P., et al.: American Society for Blood and Marrow Transplantation. Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant*, 2015, 21, s. 971–983.
- 19 Merryman, R. W. – Kim, H. T. – Zinzani, P. L., et al.: Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. *Blood*, 2017, 129, s. 1380–1388.

Dasatinib v léčbě chronické myeloidní leukemie s těžkou jaterní toxicitou předchozí léčby imatinibem

MUDr. Daniela Žáčková, Ph.D. Interní, hematologická a onkologická klinika LF MU a FN Brno

- 1 Druker, B. J. – Guilhot, F. – O'Brien, S. G., et al.: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. *N Engl J Med*, 2006, 355, s. 2408–2417.
- 2 Cohen, M. H. – Williams, G. – Johnson, J. R., et al.: Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. *Clin Cancer Res*, 2002, 8, s. 935–942.
- 3 Dostupné z: https://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf, vyhledáno 19. 4. 2018.
- 4 Talpaz, M. – Silver, R. T. – Druker, B. J., et al.: Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. *Blood*, 2002, 99, s. 1928–1937.
- 5 Cross, T. J. – Bagot, C. – Portmann, B., et al.: Imatinib mesylate as a cause of acute liver failure. *Am J Hematol*, 2006, 81, s. 189–192.
- 6 Ridruejo, E. – Cacchione, R. – Villamil, A. G., et al.: Imatinib-induced fatal acute liver failure. *World J Gastroenterol*, 2007, 13, s. 6608–6111.
- 7 Thia, T. J. – Tan, H. H. – Chuah, T. H., et al.: Imatinib mesylate-related fatal acute hepatic failure in a patient with chronic myeloid leukaemia and chronic hepatitis B infection. *Singapore Med J*, 2008, 49, s. 86–89.
- 8 Perini, G. F. – Santos, F. P. – Funke, V., et al.: Nilotinib post-liver transplantation for acute hepatic failure related to imatinib. *Leuk Res*, 2009, 33, s. 234–235.
- 9 Martínez Pascual, C. – Valdés Mas, M. – de la Peña Moral, J. M., et al.: Fulminating hepatitis for imatinib in a patient with chronic myeloid leukaemia. *Med Clin (Barc)*, 2011, 137, s. 329–330.
- 10 Harding, D. J. – MacQuillan, G. – Howman, R., et al.: Successful use of

- dasatinib after liver transplantation for imatinib-induced fulminant liver failure in chronic myeloid leukemia. *J Clin Oncol*, 2016, 34, s. 97–98.
- 11 Nacif, L. S. – Waisberg, D. R. – Pinheiro, R. S., et al.: Imatinib-induced fulminant liver failure in chronic myeloid leukemia: role of liver transplant and second-generation tyrosine kinase inhibitors: a case report. *J Med Case Rep*, 2018, 12, s. 63.
 - 12 Ohyashiki, K. – Kuriyama, Y. – Nakajima, A., et al.: Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis. *Leukemia*, 2002, 16, s. 2160–2161.
 - 13 Kong, J. H. – Yoo, S. H. – Lee, K. E., et al.: Early imatinib-mesylate-induced hepatotoxicity in chronic myelogenous leukaemia. *Acta Haematol*, 2007, 118, s. 205–208.
 - 14 Ayoub, W. S. – Geller, S. A. – Tran, T., et al.: Imatinib (Gleevec)-induced hepatotoxicity. *J Clin Gastroenterol*, 2005, 39, s. 75–77.
 - 15 James, C. – Trouette, H. – Marit, G., et al.: Histological features of acute hepatitis after imatinib mesylate treatment. *Leukemia*, 2003, 17, s. 978–979.
 - 16 Mindikoglu, A. L. – Regev, A. – Bejarano, P. A., et al.: Imatinib mesylate (gleevec) hepatotoxicity. *Dig Dis Sci*, 2007, 52, s. 598–601.
 - 17 Kikuchi, S. – Muroi, K. – Takahashi, S., et al.: Severe hepatitis and complete molecular response caused by imatinib mesylate: possible association of its seru concentration with clinical outcomes. 2009, *Leukemia Lymphoma*, 45, s. 2349–2351.
 - 18 Spataro, V.: Nilotinib in a patient with post necrotic liver cirrhosis related to imatinib. *J Clin Oncol*, 2011, 29, s. 50–52.
 - 19 Ferrero, D. – Pogliani, E. M. – Rege-Cambrin, G., et al.: Corticosteroids can reverse severe imatinib-induced hepatotoxicity. *Haematologica*, 2006, 91, 6, suppl, ECR27.
 - 20 Gupta, S. – Bhatt, V. R. – Varma, S.: Recurrent imatinib-induced hepatotoxicity in a chronic myeloid leukaemia patient access fully managed with prednisone. *BMJ Case Rep*, 2011, 10.1136/bcr11.2010.3516.
 - 21 Paech, F. – Bouitbir, J. – Krähenbühl, S.: Hepatocellular toxicity associated with tyrosine kinase inhibitors: mitochondrial damage and inhibition of glycolysis. *Front Pharmacol*, 2017, 8, s. 367.
 - 22 Harbaum, L. – Marx, A. – Goekkurt, E., et al.: Treatment with dasatinib for chronic myeloid leukemia following imatinib-induced hepatotoxicity. *Int J Hematol*, 2014, 99, s. 91–94.
 - 23 Al Sobhi, E. – Zahrani, Z. – Zevallos, E., et al.: Imatinib-induced immune hepatitis: case report and literature review. *Hematology*, 2007, 12, s. 49–53.
 - 24 Ikuta, K. – Torimoto, Y. – Jimbo, J., et al.: Severe hepatic injury caused by imatinib mesylate administered for the treatment of chronic myeloid leukemia and the efficacy of prednisolone for its management. *Int J Hematol*, 2005, 82, s. 343–346.
 - 25 Yamazaki, R. – Okamoto, S. – Chen, C. K., et al.: Successful management of liver injury caused by imatinib mesylate in a patient with previously untreated chronic myelogenous leukemia in the chronic phase. *Leuk Lymphoma*, 2006, 47, s. 1427–1430.
 - 26 Cortes, J. E. – Hochhaus, A. – LeCoutre, P. D., et al.: Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib. *Blood*, 2011, 117, s. 5600–5606.
 - 27 Hochhaus, A. – Kantarjian, H. M. – Baccarani, M., et al.: Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. *Blood*, 2007, 109, s. 2303–2309.
 - 28 Harding, D. J. – MacQuillan, G. – Howman, R., et al.: Successful use of dasatinib after liver transplantation for imatinib-induced fulminant liver failure in chronic myeloid leukemia. *J Clin Oncol*, 2016, 34, s. 97–98.
 - 29 Shah, R. R. – Morganroth, J. – Shah, D. R.: Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives. *Drug Saf*, 2013, 36, s. 491–503.
 - 30 Tokarski, J. S. – Newitt, J. A. – Chang, C. Y., et al.: The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. *Cancer Res*, 2006, 66, s. 5790–5797.
 - 31 Dostupné z: http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/000406/WC500022207.pdf, vyhledáno 19. 4. 2018.

Obinutuzumab a bendamustin – léčba relabujícího folikulárního lymfomu

MUDr. Heidi Móciková, Ph.D. Interní hematologická klinika FNKV a 3. LF UK Praha

- 1 Link, B. K. – Day, B. M. – Zhou, X., et al.: Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study. *Br J Haematol*, 2. 4. 2018, doi: 10.1111/bjh.15149, Epub před tiskem.
- 2 Jurinovic, V. – Metzner, B. – Pfreundschuh, M., et al.: Autologous stem cell transplantation for patients with early progression of follicular lymphoma: a follow-up study of two randomized trials from the German Low Grade Lymphoma Study Group. *Biol Blood Marrow Transplant*, 29. 3. 2018, pii: S1083–8791(18)30156–3, doi: 10.1016/j.bbmt.2018.03.022, Epub před tiskem.
- 3 Cheson, B. D. – Chua, N. – Mayer, J., et al.: Overall survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN Study. *J Clin Oncol*, 27. 3. 2018, CO2017763656, doi: 10.1200/JCO.2017.76.3656, Epub před tiskem.
- 4 Cheson, B. D. – Trask, P. C. – Gribben, J. G., et al.: Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone. *Ann Hematol*, 2017, 96, s. 253–259.
- 5 Sehn, L. H. – Chua, N. – Mayer, J., et al.: Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. *Lancet Oncol*, 2016, 17, s.1081–1093.
- 6 Salles, G. A. – Morschhauser, F. – Solal-Celigny, P., et al.: Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study. *J Clin Oncol*, 2013, 31, s. 2920–2926.
- 7 Radford, J. – Davies, A. – Cartron, G., et al.: Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000). *Blood*, 2013, 122, s. 1137–1143.

Léčba staršího pacienta s B-CLL kombinací obinutuzumabu s chlorambucilem

MUDr. Petr Kessler Oddělení hematologie a transfuziologie, Nemocnice Pelhřimov

- 1 Hillmen, P. – Gribben, J. G. – Follows, G. A., et al.: Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study. *J Clin Oncol*, 2014, 32, s. 1236–1241.
- 2 Gagez, A. L. – Cartron, G.: Obinutuzumab: a new class of anti-CD20 monoclonal antibody. *Curr Opin Oncol*, 2014, 26, s. 484–491.
- 3 Goede, V. – Fischer, K. – Busch, R., et al.: Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. *N Engl J Med*, 2014, 370, s. 1101–1110.
- 4 Freeman, C. L. – Dixon, M. – Houghton, R., et al.: Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab. *Leukemia*, 2016, 30, s. 1763–1766.

Recidivující respirační infekce u pacienta s refraktérnou chronickou lymfocytovou leukémiou liečeného ibrutinibom

MUDr. Ľudmila Demitrovičová, Ph.D. Oddelenie onkohematológie II., Národný onkologický ústav, Bratislava

- 1 SPC prípravku Imbruvica 140 mg capsules, 30. 8. 2017.
- 2 Byrd, J. C. – Coutre, S. E.: Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. *Blood*, 2015, 125, s. 497–2506.
- 3 Dubovsky, J. A. – Beckwith, K. A. – Natarajan, G.: Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. *Blood*, 2013, 122, s. 2539–2549.
- 4 Sun, C. – Tian, X. – Lee, S.: Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. *Blood*, 2015, 126, s. 2213–2219.
- 5 Demitrovicova, L. – Mikuskova, E. – Oravcova, I., et al.: Infectious complications in chronic lymphocytic leukemia – a retrospective analysis: single institution experience. *Neoplasma*, 2017, 64, s. 478–481.